Sawai Group Holdings Logo
JP3323040000
A2QQY4
4887.T

Sawai Group Holdings

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • SAWAI GROUP expects positive quarter: analysts see sharply improved EPS

    SAWAI GROUP will release results for the quarter ended March 31, 2026 on May 15, 2026. Three analysts forecast an average earnings per share of 27.90 JPY versus -115.73 JPY a year earlier, and five analysts see revenue at about 49.88 billion JPY (+8.87% vs 45.82 billion JPY). For the past fiscal year, nine analysts project EPS of 119.45 JPY (previously 96.54 JPY) and revenue of 203.54 billion JPY (previously 189.02 billion JPY). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Sawai Group Holdings has already paid €0.15 in dividends. The last payout was in June.

Financials

In the last quarter, Sawai Group Holdings had revenue of €282.39m and net profit of €13.98m
(EUR) September 2026
YoY
Revenue 282.39m 0.58%
Gross profit 81.43m 1.26%
Net profit 13.98m 154.26%
EBITDA 25.94m 16.70%

Fundamentals

Metric Value
Market capitalization
€1.11bn
Number of shares
115.68m
52-week high/low
€13.92 - €8.82
Dividend yield
0.88%
Dividends TTM
€0.30
Next dividend
€0.16
Beta
0.03
P/E ratio
19.41
PEG ratio
0.13
P/B ratio
1.08
P/S ratio
0.90

Company profile

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

Name
Sawai Group Holdings
CEO
Mitsuo Sawai
Headquarters Osaka, os
Japan
Website
Industry
Food Products
IPO
01/04/2021
Employees 3,630

Ticker symbols

Exchange Symbol
Japan Exchange Group
4887.T
Pnk
SWGHF
🍪

Parqet  uses cookies. Learn more